These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 20404132)

  • 1. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
    Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
    Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
    Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
    Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
    Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms.
    Oh ST
    Ther Adv Hematol; 2011 Feb; 2(1):11-9. PubMed ID: 23556072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
    Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
    Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
    Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
    Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.
    Tong W; Lodish HF
    J Exp Med; 2004 Sep; 200(5):569-80. PubMed ID: 15337790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
    Tong W; Zhang J; Lodish HF
    Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Benson KL; Mesa RA
    Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
    Gery S; Cao Q; Gueller S; Xing H; Tefferi A; Koeffler HP
    J Leukoc Biol; 2009 Jun; 85(6):957-65. PubMed ID: 19293402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the adaptor protein LNK in normal and malignant hematopoiesis.
    Gery S; Koeffler HP
    Oncogene; 2013 Jun; 32(26):3111-8. PubMed ID: 23045270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
    Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
    J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
    Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
    Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
    Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
    J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms.
    Sakr H; Clark Schneider K; Murugesan G; Bodo J; Hsi ED; Cook JR
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):147-152. PubMed ID: 27258562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
    Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
    Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
    Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
    Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.